Allison WilensMaps Research Update – Allison Wilens

Allison will be presenting this year’s MAPS research update. This will include preliminary data from MAPS’ Phase 2 clinical trials in MDMA-assisted psychotherapy for PTSD, current timelines for FDA approval, and the rationale for formation of the MAPS Public Benefit Corporation (MPBC).

 

 

 

 

 

 

About Allison

 Allison began working as Clinical Study Assistant at MAPS starting in June 2014 and has maintained the same position at the MAPS Public Benefit Corporation since it was formed in January 2015. She earned her B.S. in Biopsychology in 2014 from Tufts University, where she worked in the Psychopharmacology Lab for three years. She conducted data collection and analysis for multiple projects relating to stress, aggression, and addiction, culminating in a Senior Honors Thesis focused on the role of the NMDA receptor in mediating aggressive withdrawal symptoms in alcohol-dependent mice. She was also co-president of the Tufts chapter of Students for Sensible Drug Policy, where she worked to pass medical amnesty reform on campus and raise consciousness regarding the harmful effects of the racist War on Drugs. Allison is currently serving as MPBC’s Clinical Study Assistant, providing general administrative support to the clinical department. Allison relishes the opportunity to help deconstruct reductionist paradigms in the contemporary mental health care system and is driven by a desire to improve access to viable treatment options for those suffering from trauma- and anxiety-related disorders.